Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Magenta Therapeutics (Nasdaq: MGTA) announced promising results from a Phase 2 trial of MGTA-145 and plerixafor for stem cell mobilization in multiple myeloma patients at the ASCO Annual Meeting. All 15 patients achieved the primary endpoint of 2 million CD34+ cells per kg in up to two days, with 12 achieving it in one day. The median collection was 6.3 million cells per kg. Transplanted patients showed successful engraftment and quick recovery of blood cells. The regimen was well tolerated, with mild side effects. Final data is expected by the end of 2021.
- All 15 patients met the primary endpoint of mobilization and collection of 2 million CD34+ stem cells per kg.
- 12 out of 15 patients achieved the primary endpoint in a single day of dosing.
- The median number of total CD34+ stem cells collected was 6.3 million per kg, outperforming standard care.
- All 12 transplanted patients successfully engrafted with expected recovery times for neutrophils and platelets.
- 40% of collected stem cells were CD34+CD90+, indicating long-term engraftment potential.
- None.
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021.
“We are very pleased to see continued favorable results for MGTA-145 and plerixafor for stem cell mobilization and collection in patients with multiple myeloma,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “These results build on those previously disclosed from this study and the Phase 1 trials to further demonstrate MGTA-145 and plerixafor’s potential as a rapid, reliable, well-tolerated approach to stem cell mobilization and collection, which has positive implications for patients and donors.”
Additional Results – MGTA-145 Multiple Myeloma Phase 2 Clinical Trial
The investigator-initiated, 25-patient Phase 2 clinical trial is designed to evaluate the ability of MGTA-145, in combination with plerixafor, to mobilize and collect hematopoietic stem cells for autologous stem cell transplant in patients with multiple myeloma. This study is led by Surbhi Sidana, M.D., Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine.
Previously reported results from this trial were announced on May 12, 2021, in a published abstract for the European Hematology Association (EHA) Congress and provided preliminary data from the initial cohort of 10 patients.
Summary of cumulative results through data cut-off date:
- All patients (15/15) have met the primary endpoint of mobilization and collection of 2 million CD34+ stem cells per kg in up to two days. Twelve of 15 patients achieved the primary endpoint in a single day of dosing and collection.
- The median number of total CD34+ stem cells collected on day 1 and 2 (if needed) was 6.3 million per kg. Current standard of care with G-CSF-based regimens require a minimum of five days of dosing to initiate stem cell collection.
- All transplanted patients to date (12/12) successfully engrafted, with median recovery of neutrophils after 12.5 days and platelets after 18 days, which are within transplant expectations in multiple myeloma.
- Six patients have completed day-100 follow up, with demonstrated durable engraftment indicative of a successful transplant.
-
The collected CD34+ stem cells contain a high percentage (
40% ) of CD34+CD90+, a stem cell population associated with multi-lineage, long-term engraftment, an amount substantially greater than historically observed with G-CSF-mobilized cells. -
The regimen of MGTA-145 and plerixafor was well tolerated. Acute, transient, MGTA-145-related grade 1 bone or musculoskeletal pain was observed in
40% of patients shortly after MGTA-145 infusion, resolving within 10 minutes for all patients, and none required pain medication or other intervention.
As indicated previously, this trial has broad and clinically representative inclusion criteria and includes patients that represent the general transplant-eligible population of patients with multiple myeloma. Patients enrolled in this trial included those patients with risk factors that could impact stem cell mobilization and collection, such as myeloma-directed therapies that are known to impact stem cell collection, previous malignancy treated with chemotherapy and/or radiation, and other co-morbid conditions. Mobilization agents may be less effective in patients with multiple risk factors. Final clinical data from this trial are anticipated by the end of 2021. MGTA-145 is also being evaluated for its ability to mobilize and collect stem cells from donors for allogenic transplant in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in a Phase 2 trial, and an additional Phase 2 study is planned to initiate in patients with sickle cell disease in the second half of 2021.
ASCO Poster Presentation
Title: Phase 2 Study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma (Abstract #8023)
Author: Surbhi Sidana, M.D., Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine
Poster Session: Hematologic Malignancies – Plasma Cell Dyscrasia
Date/Time: All e-posters are now available in the ASCO Annual Meeting virtual platform
These results will also be presented as an encore at the EHA Virtual Congress, available via the conference’s virtual platform on Friday, June 11 at 3:00am EDT / 9:00am CEST.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.
Follow Magenta on Twitter: @magentatx.
Forward-Looking Statement
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magenta’s future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting pre-clinical and clinical data, the anticipated timing of clinical trials and regulatory filings, the development of product candidates and advancement of preclinical programs, the potential benefits of our product candidates, the timing, progress and success of collaborations, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether preliminary results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Magenta’s business, operations, strategy, goals and anticipated timelines, Magenta’s ongoing and planned preclinical activities, Magenta’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magenta’s timelines for regulatory submissions and Magenta’s financial position; and other risks concerning Magenta's programs and operations are described in additional detail in its Annual Report on Form 10-K filed on March 3, 2021, its Quarterly Reports on Form 10-Q and its other filings made with the Securities and Exchange Commission from time to time. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005040/en/
FAQ
What are the results of the MGTA-145 Phase 2 trial?
What is the significance of the ASCO presentation for MGTA-145?
When can we expect final data from the MGTA-145 trial?
What are the next steps for Magenta Therapeutics following the Phase 2 trial?
